Medline Reports Third Quarter and
Board of Directors authorized a $1 billion share repurchase program NORTHFIELD, Ill., Nov. 4, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline” or the “Company”) (Nasdaq: MDLN), the largest provider of medical-surgical (“med- surg”) products and supply chain solutions serving all points of care 3 , today reported its operating results for the three and nine months ended September 26, 2026.
“Medline delivered another strong quarter, with double-digit net sales growth, reflecting continued momentum across our business,” said Jim Boyle, chief executive officer of Medline. “Our commercial execution remains strong, including continued progress toward our annual total new customer signings 4 goal. We are advancing key strategic priorities, including capacity expansion and new technology across our distribution network and progress with our global quality initiatives. We remain focused on serving our customers, advancing our strategic priorities and driving sustainable long-term growth.”
Third quarter 2026 net sales increased 10.4% to $7.9 billion, compared to $7.1 billion in the third quarter 2025, with Organic Sales¹ increasing 10.5%. This was primarily driven by existing customer growth and implementation of new customer signings from 2025 and includes an $11 million increase related to an adjustment of customer repayment amounts.
Third quarter 2026 net income decreased 1.2% to $318 million, compared to $322 million in the third quarter 2025, primarily driven by increased inventory costs associated with inflation, higher operating expenses, and customer mix. This was partially offset by higher net sales and net IEEPA tariff refund benefits.
Third quarter 2026 Adjusted EBITDA¹ increased 11.8% to $960 million, compared to $859 million in the third quarter 2025, primarily driven by higher net sales and net IEEPA tariff refund benefits, partially offset by higher operating expenses and customer mix.
Third quarter 2026 diluted earnings per share and Adjusted Diluted EPS¹ were $0.22 and $0.44, respectively.
Nine months 2026 net sales increased 10.9% to $22.9 billion, compared to $20.6 billion in the 2025 period, with Organic Sales¹ increasing 10.7%. This was primarily driven by implementation of new customer signings from 2025 and existing customer growth. This includes a $78 million reduction related to the accrued customer repayments associated with IEEPA tariff refunds.
Nine months 2026 net income decreased 28.8% to $696 million, compared to $977 million in the first nine months of 2025. This was primarily driven by higher operating expenses, net losses of $316 million related to the fire at the Company’s distribution center in Tracy, California, higher cost of goods sold including the impact of tariffs, customer and segment mix, and increased inventory costs associated with inflation. This was partially offset by higher net sales and net IEEPA tariff refund benefits.
Nine months 2026 Adjusted EBITDA¹ increased 5.0% to $2.8 billion, compared to $2.7 billion in the nine months 2025, primarily driven by higher net sales and net IEEPA tariff refund benefits, partially offset by higher operating expenses, higher cost of goods sold including the impact of tariffs, and customer and segment mix.
Nine months 2026 diluted earnings per share and Adjusted Diluted EPS¹ were $0.45 and $1.27, respectively.
Net cash provided by operating activities for the first nine months of 2026 was $2.2 billion, driven by net income, net of non-cash items and inclusive of tariff refunds received, and favorable working capital.
Free Cash Flow¹ for the first nine months of 2026 was $1.8 billion, driven by net cash provided by operating activities, partially offset by $348 million of capital expenditures, primarily related to investments in automation across the distribution network, construction of new distribution centers and expansion of kitting manufacturing capacity.
In October, the Medline Board of Directors approved a share repurchase program authorizing the Company, including Medline Holdings, LP, to repurchase up to $1 billion of the Company’s outstanding shares of Class A common stock and/or units of Medline Holdings, LP, and the Company prepaid $750 million in aggregate principal amount of the 2033 Refinancing Term Loan Facility.
These actions reflect Medline’s strong cash generation and disciplined capital allocation approach, including investing in the business, continued debt reduction and opportunistic return of capital to shareholders.
The Company is raising its full year 2026 outlook for Organic Sales 2 growth to 10.0% to 10.5%, compared to its previous outlook of 9.0% to 10.0%, and reaffirming its Adjusted EBITDA 2 outlook of $3.3 billion to $3.4 billion. Consistent with prior guidance, the Adjusted EBITDA outlook does not reflect IEEPA tariff refunds, including the $324 million of net tariff benefit through the first nine months of 2026.
Following the U.S. Supreme Court’s February 2026 ruling that IEEPA tariffs were unauthorized, the Company recognized $81 million and $324 mi llion of net IEEPA tariff refund benefits during the three and nine months ended September 26, 2026, respectively. These amounts reflect tariff refunds of $70 million and $402 mil lion, respectively, recorded as a reduction of cost of goods sold. For the three month period, the net benefit also included an $11 million increase in net sales related to an adjustment of customer repayment amounts and a corresponding reduction in the related accrual. For the nine month period, the net benefit was partially offset by a $78 million reduction in net sales related to accrued customer repayments associated with IEEPA tariff refunds. These amounts were recorded entirely within the Medline Brand segment and were included in net income and Adjusted EBITDA 1 .
The Company will host a live conference call and question and answer session with investors and analysts on November 4, 2026, at 8:30 a.m. CT / 9:30 a.m. ET to discuss its third quarter and nine months 2026 earnings results. The webcast can be accessed through Medline’s Investor Relations website at ir.medline.com. A replay of the call will be available following the event through the same website.
Certain amounts and percentages presented in this press release have a rounding element. As a result, the sum of the components may not equal the totals due to rounding.
(1) Organic Sales, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Diluted EPS, Free Cash Flow, and Net Leverage are non-GAAP financial measures. See discussion of these measures and reconciliations to GAAP at the end of this press release for more information.
(2) Guidance for Adjusted EBITDA and Organic Sales is provided on a non-GAAP basis only because certain information necessary to calculate the most comparable GAAP measure is unavailable due to the uncertainty and inherent difficulty of predicting the occurrence and the future financial statement impact of such items impacting comparability, including, but not limited to, inventory-related adjustments, stock-based compensation, litigation (gains) charges, net, transaction-related costs, the impact of currency, and other non- core (gains) charges, among other items. Therefore, as a result of the uncertainty and variability of the nature and amount of future adjustments, which could be significant, the Company is unable to provide a reconciliation of these measures with reasonable certainty and without unreasonable effort. Guidance for full year 2026 Adjusted EBITDA excludes $324 million of net tariff refunds through the first nine months of 2026.
(3) Based on our 2025 net sales relative to the publicly reported net sales of med-surg products by companies that are both med-surg manufacturers and distributors.
(4) Total new customer signings refers to the estimated annual contract value of all new contracts entered into by new customers or by existing customers who are expanding their relationship with Medline, excluding renewals and extensions.
(5) In determining the amount of capital to allocate to share repurchases, the Company takes into account, among other things, its historical and expected business performance and cash and liquidity position, as well as global economic and market conditions and the market price of the Company’s common stock. The timing, manner, price and amount of any repurchases under the share repurchase program are determined by the Company in its discretion. Purchases may be effected through open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, or other means. The Company is not obligated to repurchase any specific number of shares and the program may be modified, suspended, or discontinued at any time.
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “framework,” “goal,” “guidance,” “intend,” “may,” “objective,” “outlook,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “target,” “will,” or “would,” or similar conditional or future expressions are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements related to the Company’s industry, business strategy, costs, and cost savings, goals and expectations, market position, future operations, margins, profitability, annual guidance, growth frameworks, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainties, and changes in circumstances, many of which are beyond the Company’s control, that could cause actual results to differ materially.
Factors that may cause actual results to differ from expected results include, but are not limited to, inherent risks in the Company’s global operations; the Company’s ability to derive fully the anticipated benefits from its existing or future acquisitions, joint ventures, investments, dispositions, or other strategic transactions; consolidation in the healthcare industry; competition and accelerating pricing pressure and changes in technology; changes to the U.S. and global healthcare environments; increases in shipping costs or service issues with the Company’s third-party shippers; significant challenges or delays in the Company’s sourcing of new products and technologies; the Company’s concentration in and dependence on certain healthcare provider customers and Group Purchasing Organizations; the Company’s dependence on the proper functioning of its critical facilities and distribution networks, and the impact of events outside its control, including fires and other disruptions affecting such facilities or networks, such as the Tracy facility fire; quality problems, recalls, product liability claims, and regulatory actions by the U.S. Food and Drug Administration; the Company’s failure to establish and maintain Prime Vendor relationships; the Company’s ability to realize the expected benefits from planned cost savings and business improvement initiatives; increased pressure to maintain or decrease the price of the Company’s goods and services; failure by or loss of a third-party manufacturer or supplier or other manufacturing or supply-related impacts; the Company’s reliance on the proper function, security, and availability of its information technology systems and data, as well as those of third parties throughout its global supply chain and the impact of a breach, cyber-attack, or other disruption to these systems or data; the Company’s ability to comply with extensive and complex laws and governmental regulations and the cost of any adverse regulatory action; the Company’s compliance with complex and rapidly evolving data privacy, security and data protection laws and regulations; the Company’s use or its third-party service providers’ or business partners’ use of artificial intelligence, automated decision-making and machine learning technologies and the evolving regulatory framework in this area; the Company’s ability to comply with laws and regulations relating to reimbursement of healthcare goods and services; uncertain global and domestic macro-economic and political conditions, including as a result of global geopolitical conflicts and tensions, such as the ongoing conflicts in Ukraine and the Middle East; the impact of sales of the Company’s common stock in the public market; the Company’s ability to implement its plans regarding share repurchases or to return value to stockholders, the impact of the Company’s share repurchases, or any change in the Company’s share repurchase activity; the Company’s substantial indebtedness, its ability to satisfy its debt obligations, and the significant operating and financial restrictions on the Company’s subsidiaries imposed by the Company’s debt agreements; the Company’s insurance program may not cover claims brought against it, deny coverage of claims, or be inadequate to cover future losses; the dual class structure of the Company’s common stock; the volatility of the market price of the Company’s Class A common stock; and other factors.
The Company disclaims any intent or obligation to update, revise, or withdraw any forward-looking statement in this press release, except as required by applicable law or regulation.
The Company uses its investor relations website at ir.medline.com, press releases, public conference calls and webcasts, and social media as routine channels of distribution to communicate important, and often material, information about Medline to investors and the public, including information about its financial performance and results, analyst and investor presentations, investor days, products, solutions, sustainability initiatives, and corporate governance practices. You are encouraged to follow these channels, in addition to our SEC filings, for timely information about the Company. The information on the Company’s websites is not part of this press release and is not incorporated by reference into any filings the Company makes with the SEC.
The non-GAAP financial measures provided in this press release should be viewed in addition to, and not as an alternative for, results prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
To supplement the financial information provided, the Company has presented Organic Sales, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Diluted EPS, Free Cash Flow, and Net Leverage, which are considered non-GAAP financial measures. The non-GAAP financial measures presented may differ from similarly titled non-GAAP financial measures presented by other companies, and other companies may not define these non-GAAP financial measures in the same way. These measures are not substitutes for their comparable GAAP financial measures, such as net income/(loss), net income margin, diluted earnings per share, net cash from operating activities, net sales, or other measures prescribed by GAAP, and there are limitations to using non-GAAP financial measures.
Management uses these non-GAAP financial measures to assist in comparing the Company’s performance on a consistent basis for purposes of business decision making by removing the impact of certain items that management believes do not directly reflect the Company’s ongoing operating performance. The Company believes Organic Sales, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Diluted EPS provide important comparability of ongoing operating performance, allowing investors and management to assess the Company’s operating performance on a consistent basis. The Company believes Free Cash Flow and Net Leverage provide a measure of the Company’s core operating performance, the cash-generating capabilities of the Company’s business operations, and are factors used in determining the Company’s borrowing capacity and the amount of cash available for debt repayments, acquisitions, and other corporate purposes.
Management believes that presenting the Company’s non-GAAP financial measures is useful to investors because it (i) provides investors with meaningful supplemental information regarding financial performance by excluding certain items that we do not consider indicative of our ongoing operating performance, (ii) permits investors to view performance using the same tools that management uses to budget, make operating and strategic decisions, and evaluate historical performance, and (iii) otherwise provides supplemental information that may be useful to investors in evaluating the Company’s results. The Company believes that the presentation of these non-GAAP financial measures, when considered together with the corresponding GAAP financial measures and the reconciliations to those measures, provides investors with greater understanding of the factors and trends affecting the Company’s business than could be obtained absent these disclosures.
is defined as net sales excluding, when they occur, the impact of acquisitions, divestitures, and changes in foreign exchange rates from the net sales changes. The changes in foreign currency exchange rates from the net sales changes are calculated by translating current period GAAP results at the prior period foreign currency exchange rates and comparing these amounts to the current period GAAP results at the current period foreign currency exchange rates.
provision for income taxes, (iii) depreciation and amortization, (iv) inventory-
charges, net, (vii) transaction-related costs, and (viii) other non-core (gains)
is defined as net income (loss) adjusted for (i) intangible asset amortization, (ii) inventory-related adjustments, (iii) stock-based compensation, (iv) litigation (gains) charges, net, (v) transaction-related costs, (vi) other non- core (gains) charges, and (vii) tax impacts related to non-GAAP adjustments, noncontrolling interests conversion, and retained tax receivable agreement (“TRA”) benefits.
is defined as Adjusted Net Income divided by adjusted weighted-average number of shares of common stock, diluted. The adjusted weighted shares calculation assumes the impact of certain antidilutive securities that were excluded from the U.S. GAAP diluted earnings per share.
is defined as net cash provided by/(used for) operating activities less net capital expenditures. The use of this non-GAAP measure does not imply or represent the residual cash flow for discretionary expenditures since the Company has certain non-discretionary obligations such as debt service that are not deducted from the measure.
is defined as net debt (total debt less cash, cash equivalents and short-term investments) divided by Adjusted EBITDA.
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries. To learn more about how Medline makes healthcare run better, visit www.medline.com .
As of September (in millions, 26, except per 2026 As of December share amounts) (Unaudited) 31, 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets Cash and cash $ 2,321 $ 1,939 equivalents Short-term 1,287 — investments Trade accounts receivable, net of allowance for credit losses of $148 and 3,794 3,533 $152 as of September 26, 2026 and December 31, 2025, respectively Inventories 4,806 4,769 Other current 445 438 assets Total current 12,653 10,679 assets Property, plant, and 4,728 4,778 equipment, net Other non-current assets Goodwill 8,073 8,079 Intangible 13,377 13,893 assets, net Deferred tax 833 583 assets Other long-term 514 472 assets Total other non-current 22,797 23,027 assets Total assets $ 40,178 $ 38,484 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Current portion of long-term borrowings $ 29 $ 77 and other short-term borrowings Accounts 1,209 961 payable Accrued expenses and 1,891 1,452 other current liabilities Total current 3,129 2,490 liabilities Non-current liabilities Long-term borrowings, 12,551 12,484 less current portion Tax receivable agreement 4,403 3,542 liability Other long-term 709 682 liabilities Total non-current 17,663 16,708 liabilities Total $ 20,792 $ 19,198 liabilities Commitments and contingencies Stockholders’ equity Class A common stock, par value $0.0001 per share; 50,000 shares authorized; 879 and 812 shares — — issued and outstanding as of September 26, 2026 and December 31, 2025, respectively Class B common stock, par value $0.0001 per share; 50,000 shares authorized; 437 and 502 shares — — issued and outstanding as of September 26, 2026 and December 31, 2025, respectively Preferred stock, par value $0.0001; 5,000 shares — — authorized; no shares issued and outstanding Additional 11,428 10,717 paid-in capital Retained earnings 377 -7 (accumulated deficit) Accumulated other comprehensive -4 27 (loss) income Total Medline Inc. 11,801 10,737 stockholders’ equity Noncontrolling 7,585 8,549 interests Total stockholders’ 19,386 19,286 equity Total liabilities and $ 40,178 $ 38,484 stockholders’ equity
(1) The organizational structure includes Corporate & Other which consists of expenses related to centralized corporate functions, such as finance, information technology, legal, human resources, and internal audit.
(1) Represents the non-cash impact of last-in, first-out reserve changes attributable to changes in inventory costs.
(2) The nine months ended September 27, 2025, represents a settlement adjustment of $(8) million related to the ethylene oxide litigation, $(43) million related to settlement of an intellectual property dispute, and $4 million related to other legal settlements.
(3) The three and nine months ended September 26, 2026 and September 27, 2025, respectively, include $30 million, $4 million, $87 million and $12 million of expenses related to our IPO and subsequent offerings, consisting of legal, accounting, and advisory fees, as well as one-time employee bonuses, which are subject to an ongoing service requirement. The three months ended September 27, 2025 and the nine months ended September 26, 2026 and September 27, 2025 include $8 million, $7 million, and $23 million of acquisition and integration-related costs and adjustments, respectively. (4) The three and nine months ended September 26, 2026 primarily include: a. Costs related to specified transformation and implementation projects of $11 million and $34 million, respectively.
b. Loss on debt extinguishment and other debt refinancing costs and fees related to specified financing transactions of $1 million and $46 million, respectively.
c. The impact attributable to a fire at the distribution center in Tracy, California, net of insurance proceeds of $(20) million and $316 million, respectively.
d. Costs attributable to specified remediation activities undertaken in response to FDA observations and warning letters of $13 million.
e. Recall and discontinuation costs related to Medline Brand beds of $13 million.
f. Costs related to specified transformation and implementation projects of $3 million and $15 million, respectively.
g. Loss on debt extinguishment and other debt refinancing costs and fees related to specified financing transactions of $6 million.
h. Foreign exchange losses directly attributable to the remeasurement of euro- denominated term loans of $9 million and $84 million, respectively.
The nine months ended September 27, 2025 also includes $32 million credit loss expense related to certain customer receivable.
(5) Net income margin represents net income divided by net sales and Adjusted EBITDA Margin represents Adjusted EBITDA divided by net sales.
(6) Not Meaningful Reconciliation of Net Income to Adjusted Net Income and Adjusted Diluted EPS
(in millions, except number of shares and per Three share months September Nine months September amounts) ended 26, 2026 ended 26, 2026 ────────────────────────────────────────────────────────────────────────────── Net income $ 318 $ 696 Intangible asset 176 529 amortizat… Inventory… 122 154 adjustmen… Stock-bas… compensat… 29 81 expense Transacti… 30 94 costs(2) Other non-core 16 413 charges(3) Tax effect on -96 -231 non-GAAP adjustmen… Tax provision on conversion -25 -82 of noncontro… interests… Tax impact of retained 7 22 TRA benefits(… Adjusted $ 577 $ 1,676 Net Income Weighted-… number of Class A common 1,316,405,… 1,316,765… stock outstandi… (Diluted) Anti-dilu… 2,224,134 1,142,702 securitie… Adjusted weighted-… common 1,318,630,… 1,317,908… stock outstandi… (Diluted) Diluted earnings $ 0.22 $ 0.45 per share Adjusted Diluted $ 0.44 $ 1.27 EPS
(1) Represents the non-cash impact of last-in, first-out reserve changes attributable to changes in inventory costs.
(2) The three and nine months ended September 26, 2026, respectively, include $30 million and $87 million expenses related to our IPO and subsequent offerings, consisting of legal, accounting, and advisory fees, as well as one- time employee bonuses, which are subject to an ongoing service requirement. The nine months ended September 26, 2026 also include $7 million of acquisition and integration-related costs and adjustments, respectively.
a. Costs related to specified transformation and implementation projects of $11 million and $34 million, respectively.
b. Loss on debt extinguishment and other debt refinancing costs and fees related to specified financing transactions of $1 million and $46 million, respectively.
c. The impact attributable to a fire at the distribution center in Tracy, California, net of insurance proceeds of $(20) million and $316 million, respectively.
d. Costs attributable to specified remediation activities undertaken in response to FDA observations and warning letters of $13 million.
e. Recall and discontinuation costs related to Medline Brand beds of $13 million.
(4) Non-GAAP adjustments are tax effected using an estimated effective tax rate of 25%. Stock-based compensation expense related to partnership units is not tax deductible and, therefore, not tax effected.
(5) Represents incremental tax provision assuming 100% ownership by Medline Inc., using an estimated effective tax rate of 25%, applied to the income before income taxes on our unaudited Condensed Consolidated Statements of Income.
(6) Represents the 10% benefit that we retain for the shared tax benefits related to the TRA.
(7) Assumes full exchange of noncontrolling interest units for Class A common stock and the effect of securities that were anti-dilutive during the three and nine months ended September 26, 2026. Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow
Full text with the tables
November 4, 2026
Medline Reports Third Quarter and
Nine Months 2026 Results
•
Third quarter net sales of $7.9 billion, an increase of 10.4%
•
Third quarter net income of $318 million, a decrease of 1.2%
•
Third quarter Adjusted EBITDA
1
of $1.0 billion, an increase of 11.8%
•
Nine months net sales of $22.9 billion, an increase of 10.9%
•
Nine months net income of $696 million, a decrease of 28.8%
•
Nine months Adjusted EBITDA
1
of $2.8 billion, an increase of 5.0%
•
Raising full year 2026 Organic Sales
2
guidance to 10.0% to 10.5% from 9.0% to 10.0% and reaffirming Adjusted EBITDA
2
guidance of $3.3 billion to $3.4 billion
•
Board of Directors authorized a $1 billion share repurchase program
NORTHFIELD, Ill., Nov. 4, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline” or
the “Company”) (Nasdaq: MDLN), the largest provider of medical-surgical (“med-
surg”) products and supply chain solutions serving all points of care 3 , today
reported its operating results for the three and nine months ended September 26,
2026.
“Medline delivered another strong quarter, with double-digit net sales growth,
reflecting continued momentum across our business,” said Jim Boyle, chief
executive officer of Medline. “Our commercial execution remains strong,
including continued progress toward our annual total new customer signings 4
goal. We are advancing key strategic priorities, including capacity expansion
and new technology across our distribution network and progress with our global
quality initiatives. We remain focused on serving our customers, advancing our
strategic priorities and driving sustainable long-term growth.”
Third Quarter 2026 Results
Third quarter 2026 net sales increased 10.4% to $7.9 billion, compared to $7.1
billion in the third quarter 2025, with Organic Sales¹ increasing 10.5%. This
was primarily driven by existing customer growth and implementation of new
customer signings from 2025 and includes an $11 million increase related to an
adjustment of customer repayment amounts.
Third quarter 2026 net income decreased 1.2% to $318 million, compared to $322
million in the third quarter 2025, primarily driven by increased inventory costs
associated with inflation, higher operating expenses, and customer mix. This was
partially offset by higher net sales and net IEEPA tariff refund benefits.
Third quarter 2026 Adjusted EBITDA¹ increased 11.8% to $960 million, compared to
$859 million in the third quarter 2025, primarily driven by higher net sales and
net IEEPA tariff refund benefits, partially offset by higher operating expenses
and customer mix.
Third quarter 2026 diluted earnings per share and Adjusted Diluted EPS¹ were
$0.22 and $0.44, respectively.
Nine Months 2026 Results
Nine months 2026 net sales increased 10.9% to $22.9 billion, compared to $20.6
billion in the 2025 period, with Organic Sales¹ increasing 10.7%. This was
primarily driven by implementation of new customer signings from 2025 and
existing customer growth. This includes a $78 million reduction related to the
accrued customer repayments associated with IEEPA tariff refunds.
Nine months 2026 net income decreased 28.8% to $696 million, compared to $977
million in the first nine months of 2025. This was primarily driven by higher
operating expenses, net losses of $316 million related to the fire at the
Company’s distribution center in Tracy, California, higher cost of goods sold
including the impact of tariffs, customer and segment mix, and increased
inventory costs associated with inflation. This was partially offset by higher
net sales and net IEEPA tariff refund benefits.
Nine months 2026 Adjusted EBITDA¹ increased 5.0% to $2.8 billion, compared to
$2.7 billion in the nine months 2025, primarily driven by higher net sales and
net IEEPA tariff refund benefits, partially offset by higher operating expenses,
higher cost of goods sold including the impact of tariffs, and customer and
segment mix.
Nine months 2026 diluted earnings per share and Adjusted Diluted EPS¹ were $0.45
and $1.27, respectively.
Net cash provided by operating activities for the first nine months of 2026 was
$2.2 billion, driven by net income, net of non-cash items and inclusive of
tariff refunds received, and favorable working capital.
Free Cash Flow¹ for the first nine months of 2026 was $1.8 billion, driven by
net cash provided by operating activities, partially offset by $348 million of
capital expenditures, primarily related to investments in automation across the
distribution network, construction of new distribution centers and expansion of
kitting manufacturing capacity.
Capital Allocation
In October, the Medline Board of Directors approved a share repurchase program
authorizing the Company, including Medline Holdings, LP, to repurchase up to $1
billion of the Company’s outstanding shares of Class A common stock and/or units
of Medline Holdings, LP, and the Company prepaid $750 million in aggregate
principal amount of the 2033 Refinancing Term Loan Facility.
These actions reflect Medline’s strong cash generation and disciplined capital
allocation approach, including investing in the business, continued debt
reduction and opportunistic return of capital to shareholders.
2026 Guidance
The Company is raising its full year 2026 outlook for Organic Sales 2 growth to
10.0% to 10.5%, compared to its previous outlook of 9.0% to 10.0%, and
reaffirming its Adjusted EBITDA 2 outlook of $3.3 billion to $3.4 billion.
Consistent with prior guidance, the Adjusted EBITDA outlook does not reflect
IEEPA tariff refunds, including the $324 million of net tariff benefit through
the first nine months of 2026.
IEEPA Tariff Refunds and Related Customer Repayments
Following the U.S. Supreme Court’s February 2026 ruling that IEEPA tariffs were
unauthorized, the Company recognized $81 million and $324 mi llion of net IEEPA
tariff refund benefits during the three and nine months ended September 26,
2026, respectively. These amounts reflect tariff refunds of $70 million and $402
mil lion, respectively, recorded as a reduction of cost of goods sold. For the
three month period, the net benefit also included an $11 million increase in net
sales related to an adjustment of customer repayment amounts and a corresponding
reduction in the related accrual. For the nine month period, the net benefit was
partially offset by a $78 million reduction in net sales related to accrued
customer repayments associated with IEEPA tariff refunds. These amounts were
recorded entirely within the Medline Brand segment and were included in net
income and Adjusted EBITDA 1 .
Webcast and Conference Call Instructions
The Company will host a live conference call and question and answer session
with investors and analysts on November 4, 2026, at 8:30 a.m. CT / 9:30 a.m. ET
to discuss its third quarter and nine months 2026 earnings results. The webcast
can be accessed through Medline’s Investor Relations website at ir.medline.com.
A replay of the call will be available following the event through the same
website.
End Notes and Use of Non-GAAP Financial Measures
Certain amounts and percentages presented in this press release have a rounding
element. As a result, the sum of the components may not equal the totals due to
rounding.
(1) Organic Sales, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income,
Adjusted Diluted EPS, Free Cash Flow, and Net Leverage are non-GAAP financial
measures. See discussion of these measures and reconciliations to GAAP at the
end of this press release for more information.
(2) Guidance for Adjusted EBITDA and Organic Sales is provided on a non-GAAP
basis only because certain information necessary to calculate the most
comparable GAAP measure is unavailable due to the uncertainty and inherent
difficulty of predicting the occurrence and the future financial statement
impact of such items impacting comparability, including, but not limited to,
inventory-related adjustments, stock-based compensation, litigation (gains)
charges, net, transaction-related costs, the impact of currency, and other non-
core (gains) charges, among other items. Therefore, as a result of the
uncertainty and variability of the nature and amount of future adjustments,
which could be significant, the Company is unable to provide a reconciliation of
these measures with reasonable certainty and without unreasonable effort.
Guidance for full year 2026 Adjusted EBITDA excludes $324 million of net tariff
refunds through the first nine months of 2026.
(3) Based on our 2025 net sales relative to the publicly reported net sales of
med-surg products by companies that are both med-surg manufacturers and
distributors.
(4) Total new customer signings refers to the estimated annual contract value of
all new contracts entered into by new customers or by existing customers who are
expanding their relationship with Medline, excluding renewals and extensions.
(5) In determining the amount of capital to allocate to share repurchases, the
Company takes into account, among other things, its historical and expected
business performance and cash and liquidity position, as well as global economic
and market conditions and the market price of the Company’s common stock. The
timing, manner, price and amount of any repurchases under the share repurchase
program are determined by the Company in its discretion. Purchases may be
effected through open market transactions, privately negotiated transactions,
transactions structured through investment banking institutions, or other means.
The Company is not obligated to repurchase any specific number of shares and the
program may be modified, suspended, or discontinued at any time.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking
statements include all statements that are not historical facts. Words such as
“anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,”
“estimate,” “expect,” “foreseeable,” “framework,” “goal,” “guidance,” “intend,”
“may,” “objective,” “outlook,” “plan,” “potentially,” “predict,” “project,”
“seek,” “should,” “target,” “will,” or “would,” or similar conditional or future
expressions are intended to identify forward-looking statements. Examples of
forward-looking statements include, but are not limited to, statements related
to the Company’s industry, business strategy, costs, and cost savings, goals and
expectations, market position, future operations, margins, profitability, annual
guidance, growth frameworks, and other financial and operating information. The
forward-looking statements are based on management’s current expectations and
are subject to various risks, uncertainties, and changes in circumstances, many
of which are beyond the Company’s control, that could cause actual results to
differ materially.
Factors that may cause actual results to differ from expected results include,
but are not limited to, inherent risks in the Company’s global operations; the
Company’s ability to derive fully the anticipated benefits from its existing or
future acquisitions, joint ventures, investments, dispositions, or other
strategic transactions; consolidation in the healthcare industry; competition
and accelerating pricing pressure and changes in technology; changes to the U.S.
and global healthcare environments; increases in shipping costs or service
issues with the Company’s third-party shippers; significant challenges or delays
in the Company’s sourcing of new products and technologies; the Company’s
concentration in and dependence on certain healthcare provider customers and
Group Purchasing Organizations; the Company’s dependence on the proper
functioning of its critical facilities and distribution networks, and the impact
of events outside its control, including fires and other disruptions affecting
such facilities or networks, such as the Tracy facility fire; quality problems,
recalls, product liability claims, and regulatory actions by the U.S. Food and
Drug Administration; the Company’s failure to establish and maintain Prime
Vendor relationships; the Company’s ability to realize the expected benefits
from planned cost savings and business improvement initiatives; increased
pressure to maintain or decrease the price of the Company’s goods and services;
failure by or loss of a third-party manufacturer or supplier or other
manufacturing or supply-related impacts; the Company’s reliance on the proper
function, security, and availability of its information technology systems and
data, as well as those of third parties throughout its global supply chain and
the impact of a breach, cyber-attack, or other disruption to these systems or
data; the Company’s ability to comply with extensive and complex laws and
governmental regulations and the cost of any adverse regulatory action; the
Company’s compliance with complex and rapidly evolving data privacy, security
and data protection laws and regulations; the Company’s use or its third-party
service providers’ or business partners’ use of artificial intelligence,
automated decision-making and machine learning technologies and the evolving
regulatory framework in this area; the Company’s ability to comply with laws and
regulations relating to reimbursement of healthcare goods and services;
uncertain global and domestic macro-economic and political conditions, including
as a result of global geopolitical conflicts and tensions, such as the ongoing
conflicts in Ukraine and the Middle East; the impact of sales of the Company’s
common stock in the public market; the Company’s ability to implement its plans
regarding share repurchases or to return value to stockholders, the impact of
the Company’s share repurchases, or any change in the Company’s share repurchase
activity; the Company’s substantial indebtedness, its ability to satisfy its
debt obligations, and the significant operating and financial restrictions on
the Company’s subsidiaries imposed by the Company’s debt agreements; the
Company’s insurance program may not cover claims brought against it, deny
coverage of claims, or be inadequate to cover future losses; the dual class
structure of the Company’s common stock; the volatility of the market price of
the Company’s Class A common stock; and other factors.
The Company disclaims any intent or obligation to update, revise, or withdraw
any forward-looking statement in this press release, except as required by
applicable law or regulation.
The Company uses its investor relations website at ir.medline.com, press
releases, public conference calls and webcasts, and social media as routine
channels of distribution to communicate important, and often material,
information about Medline to investors and the public, including information
about its financial performance and results, analyst and investor presentations,
investor days, products, solutions, sustainability initiatives, and corporate
governance practices. You are encouraged to follow these channels, in addition
to our SEC filings, for timely information about the Company. The information on
the Company’s websites is not part of this press release and is not incorporated
by reference into any filings the Company makes with the SEC.
Non-GAAP Financial Measures
The non-GAAP financial measures provided in this press release should be viewed
in addition to, and not as an alternative for, results prepared in accordance
with accounting principles generally accepted in the United States of America
(“GAAP”).
To supplement the financial information provided, the Company has presented
Organic Sales, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income,
Adjusted Diluted EPS, Free Cash Flow, and Net Leverage, which are considered
non-GAAP financial measures. The non-GAAP financial measures presented may
differ from similarly titled non-GAAP financial measures presented by other
companies, and other companies may not define these non-GAAP financial measures
in the same way. These measures are not substitutes for their comparable GAAP
financial measures, such as net income/(loss), net income margin, diluted
earnings per share, net cash from operating activities, net sales, or other
measures prescribed by GAAP, and there are limitations to using non-GAAP
financial measures.
Management uses these non-GAAP financial measures to assist in comparing the
Company’s performance on a consistent basis for purposes of business decision
making by removing the impact of certain items that management believes do not
directly reflect the Company’s ongoing operating performance. The Company
believes Organic Sales, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net
Income, and Adjusted Diluted EPS provide important comparability of ongoing
operating performance, allowing investors and management to assess the Company’s
operating performance on a consistent basis. The Company believes Free Cash Flow
and Net Leverage provide a measure of the Company’s core operating performance,
the cash-generating capabilities of the Company’s business operations, and are
factors used in determining the Company’s borrowing capacity and the amount of
cash available for debt repayments, acquisitions, and other corporate purposes.
Management believes that presenting the Company’s non-GAAP financial measures is
useful to investors because it (i) provides investors with meaningful
supplemental information regarding financial performance by excluding certain
items that we do not consider indicative of our ongoing operating performance,
(ii) permits investors to view performance using the same tools that management
uses to budget, make operating and strategic decisions, and evaluate historical
performance, and (iii) otherwise provides supplemental information that may be
useful to investors in evaluating the Company’s results. The Company believes
that the presentation of these non-GAAP financial measures, when considered
together with the corresponding GAAP financial measures and the reconciliations
to those measures, provides investors with greater understanding of the factors
and trends affecting the Company’s business than could be obtained absent these
disclosures.
Definitions
Organic Sales
is defined as net sales excluding, when they occur, the impact of acquisitions,
divestitures, and changes in foreign exchange rates from the net sales changes.
The changes in foreign currency exchange rates from the net sales changes are
calculated by translating current period GAAP results at the prior period
foreign currency exchange rates and comparing these amounts to the current
period GAAP results at the current period foreign currency exchange rates.
Adjusted EBITDA
is defined as net income (loss) adjusted for (i) interest expense, net, (ii)
provision for income taxes, (iii) depreciation and amortization, (iv) inventory-
related adjustments, (v) stock-based compensation, (vi) litigation (gains)
charges, net, (vii) transaction-related costs, and (viii) other non-core (gains)
charges.
Adjusted EBITDA Margin
is defined as Adjusted EBITDA divided by net sales.
Adjusted Net Income
is defined as net income (loss) adjusted for (i) intangible asset amortization,
(ii) inventory-related adjustments, (iii) stock-based compensation, (iv)
litigation (gains) charges, net, (v) transaction-related costs, (vi) other non-
core (gains) charges, and (vii) tax impacts related to non-GAAP adjustments,
noncontrolling interests conversion, and retained tax receivable agreement
(“TRA”) benefits.
Adjusted Diluted EPS
is defined as Adjusted Net Income divided by adjusted weighted-average number of
shares of common stock, diluted. The adjusted weighted shares calculation
assumes the impact of certain antidilutive securities that were excluded from
the U.S. GAAP diluted earnings per share.
Free Cash Flow
is defined as net cash provided by/(used for) operating activities less net
capital expenditures. The use of this non-GAAP measure does not imply or
represent the residual cash flow for discretionary expenditures since the
Company has certain non-discretionary obligations such as debt service that are
not deducted from the measure.
Net Leverage
is defined as net debt (total debt less cash, cash equivalents and short-term
investments) divided by Adjusted EBITDA.
Medline
Medline is the largest provider of medical-surgical products and supply chain
solutions serving all points of care. Through its broad product portfolio,
resilient supply chain and leading clinical solutions, Medline helps healthcare
providers improve their clinical, financial and operational outcomes.
Headquartered in Northfield, Ill., the company employs more than 45,000 people
worldwide and operates in more than 100 countries. To learn more about how
Medline makes healthcare run better, visit www.medline.com .
Investor Relations:
Karen King
Global Head of Investor Relations
Patrick Flaherty
Director, Investor Relations
(847) 247-7222
[email protected]
Media Relations:
Ben Fox
Vice President, Corporate Communications
(224) 327-9999
[email protected]
Financial Tables
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)
$
…
──────────────────────────────────────────────────────────────────────────────
… …
… …
… …
… …
1 …
…
… …
… …
… …
…
…
… …
… …
…
… …
…
… …
(1) Not Meaningful
CONDENSED CONSOLIDATED BALANCE SHEETS
As of September
(in millions, 26,
except per 2026 As of December
share amounts) (Unaudited) 31, 2025
──────────────────────────────────────────────────────────────────────────────
ASSETS
Current assets
Cash and cash $ 2,321 $ 1,939
equivalents
Short-term 1,287 —
investments
Trade accounts
receivable, net
of
allowance for
credit losses
of $148 and 3,794 3,533
$152 as of
September 26,
2026 and
December 31,
2025,
respectively
Inventories 4,806 4,769
Other current 445 438
assets
Total current 12,653 10,679
assets
Property,
plant, and 4,728 4,778
equipment, net
Other
non-current
assets
Goodwill 8,073 8,079
Intangible 13,377 13,893
assets, net
Deferred tax 833 583
assets
Other long-term 514 472
assets
Total other
non-current 22,797 23,027
assets
Total assets $ 40,178 $ 38,484
LIABILITIES AND
STOCKHOLDERS'
EQUITY
Current
liabilities
Current portion
of long-term
borrowings $ 29 $ 77
and other
short-term
borrowings
Accounts 1,209 961
payable
Accrued
expenses and 1,891 1,452
other current
liabilities
Total current 3,129 2,490
liabilities
Non-current
liabilities
Long-term
borrowings, 12,551 12,484
less current
portion
Tax receivable
agreement 4,403 3,542
liability
Other long-term 709 682
liabilities
Total
non-current 17,663 16,708
liabilities
Total $ 20,792 $ 19,198
liabilities
Commitments and
contingencies
Stockholders’
equity
Class A common
stock, par
value $0.0001
per share;
50,000 shares
authorized; 879
and 812 shares — —
issued and
outstanding as
of September
26, 2026 and
December 31,
2025,
respectively
Class B common
stock, par
value $0.0001
per share;
50,000 shares
authorized; 437
and 502 shares — —
issued and
outstanding as
of September
26, 2026 and
December 31,
2025,
respectively
Preferred
stock, par
value $0.0001;
5,000 shares — —
authorized; no
shares
issued and
outstanding
Additional 11,428 10,717
paid-in capital
Retained
earnings 377 -7
(accumulated
deficit)
Accumulated
other
comprehensive -4 27
(loss)
income
Total Medline
Inc. 11,801 10,737
stockholders’
equity
Noncontrolling 7,585 8,549
interests
Total
stockholders’ 19,386 19,286
equity
Total
liabilities and $ 40,178 $ 38,484
stockholders’
equity
Condensed Consolidated Cash Flow Highlights
(unaudited)
($
mi…
Se… Nine Sep…
26, mon… 27, $ %
20… end… 2025 Cha… Cha…
──────────────────────────────────────────────────────────────────────────────
Net
ca…
pr… $ 2,… $ 1,… $ 637 42.0 %
by
op…
ac…
Net
ca…
us… -1… -3… -1… NM…
in
in…
ac…
Net
ca…
us… -2… -4… 278 -55… %
in
fi…
ac…
Ef…
of
ex… -14 24 -38 NM…
ra…
ch…
Net
ch…
in
ca…
ca… $ 381 $ 705 $ -3… -46… %
eq…
and
re…
ca…
(1) Not Meaningful
Segment Net Sales and Adjusted EBITDA Margin
(unaudited)
$
…
──────────────────────────────────────────────────────────────────────────────
… …
… …
… …
… …
… …
(1) The organizational structure includes Corporate & Other which consists of
expenses related to centralized corporate functions, such as finance,
information technology, legal, human resources, and internal audit.
Reconciliation of Net Sales to Organic Sales
(unaudited)
($ Thr… Nine
mi… mon… mon…
ex… end… end…
pe… Amo… Per… Amo… Per…
──────────────────────────────────────────────────────────────────────────────
Net
sa…
for
pe… $ 7,8… $ 22,…
en…
Se…
26,
20…
Net
sa…
for
pe… 7,1… 20,…
en…
Se…
27,
20…
Net
sa… 741 10.4 % 2,2… 10.9 %
gr…
Im…
fr…
ch…
in -7 -0.1 % 35 0.2 %
fo…
ex…
ra…
Or… $ 748 10.5 % $ 2,2… 10.7 %
Sa…
Reconciliation of Net Income to Adjusted EBITDA and Net Leverage
(unaudited)
…
$ % …
… … …
──────────────────────────────────────────────────────────────────────────────
$ % $ … … …
% … … …
… … …
% … … …
… … …
% … … …
% … …
… … …
% … …
$ % $ … … …
… … %
… … %
(1) Represents the non-cash impact of last-in, first-out reserve changes
attributable to changes in inventory costs.
(2) The nine months ended September 27, 2025, represents a settlement adjustment
of $(8) million related to the ethylene oxide litigation, $(43) million related
to settlement of an intellectual property dispute, and $4 million related to
other legal settlements.
(3) The three and nine months ended September 26, 2026 and September 27, 2025,
respectively, include $30 million, $4 million, $87 million and $12 million of
expenses related to our IPO and subsequent offerings, consisting of legal,
accounting, and advisory fees, as well as one-time employee bonuses, which are
subject to an ongoing service requirement. The three months ended September 27,
2025 and the nine months ended September 26, 2026 and September 27, 2025 include
$8 million, $7 million, and $23 million of acquisition and integration-related
costs and adjustments, respectively.
(4) The three and nine months ended September 26, 2026 primarily include:
a. Costs related to specified transformation and implementation projects of $11
million and $34 million, respectively.
b. Loss on debt extinguishment and other debt refinancing costs and fees related
to specified financing transactions of $1 million and $46 million, respectively.
c. The impact attributable to a fire at the distribution center in Tracy,
California, net of insurance proceeds of $(20) million and $316 million,
respectively.
d. Costs attributable to specified remediation activities undertaken in response
to FDA observations and warning letters of $13 million.
e. Recall and discontinuation costs related to Medline Brand beds of $13
million.
The three and nine months ended September 27, 2025 primarily include:
f. Costs related to specified transformation and implementation projects of $3
million and $15 million, respectively.
g. Loss on debt extinguishment and other debt refinancing costs and fees related
to specified financing transactions of $6 million.
h. Foreign exchange losses directly attributable to the remeasurement of euro-
denominated term loans of $9 million and $84 million, respectively.
The nine months ended September 27, 2025 also includes $32 million credit loss
expense related to certain customer receivable.
(5) Net income margin represents net income divided by net sales and Adjusted
EBITDA Margin represents Adjusted EBITDA divided by net sales.
(6) Not Meaningful
Reconciliation of Net Income to Adjusted Net Income and Adjusted Diluted EPS
(unaudited)
(in
millions,
except
number of
shares and
per Three
share months September Nine months September
amounts) ended 26, 2026 ended 26, 2026
──────────────────────────────────────────────────────────────────────────────
Net income $ 318 $ 696
Intangible
asset 176 529
amortizat…
Inventory… 122 154
adjustmen…
Stock-bas…
compensat… 29 81
expense
Transacti… 30 94
costs(2)
Other
non-core 16 413
charges(3)
Tax effect
on -96 -231
non-GAAP
adjustmen…
Tax
provision
on
conversion -25 -82
of
noncontro…
interests…
Tax impact
of
retained 7 22
TRA
benefits(…
Adjusted $ 577 $ 1,676
Net Income
Weighted-…
number of
Class A
common 1,316,405,… 1,316,765…
stock
outstandi…
(Diluted)
Anti-dilu… 2,224,134 1,142,702
securitie…
Adjusted
weighted-…
common 1,318,630,… 1,317,908…
stock
outstandi…
(Diluted)
Diluted
earnings $ 0.22 $ 0.45
per share
Adjusted
Diluted $ 0.44 $ 1.27
EPS
(1) Represents the non-cash impact of last-in, first-out reserve changes
attributable to changes in inventory costs.
(2) The three and nine months ended September 26, 2026, respectively, include
$30 million and $87 million expenses related to our IPO and subsequent
offerings, consisting of legal, accounting, and advisory fees, as well as one-
time employee bonuses, which are subject to an ongoing service requirement. The
nine months ended September 26, 2026 also include $7 million of acquisition and
integration-related costs and adjustments, respectively.
(3) The three and nine months ended September 26, 2026 primarily include:
a. Costs related to specified transformation and implementation projects of $11
million and $34 million, respectively.
b. Loss on debt extinguishment and other debt refinancing costs and fees related
to specified financing transactions of $1 million and $46 million, respectively.
c. The impact attributable to a fire at the distribution center in Tracy,
California, net of insurance proceeds of $(20) million and $316 million,
respectively.
d. Costs attributable to specified remediation activities undertaken in response
to FDA observations and warning letters of $13 million.
e. Recall and discontinuation costs related to Medline Brand beds of $13
million.
(4) Non-GAAP adjustments are tax effected using an estimated effective tax rate
of 25%. Stock-based compensation expense related to partnership units is not tax
deductible and, therefore, not tax effected.
(5) Represents incremental tax provision assuming 100% ownership by Medline
Inc., using an estimated effective tax rate of 25%, applied to the income before
income taxes on our unaudited Condensed Consolidated Statements of Income.
(6) Represents the 10% benefit that we retain for the shared tax benefits
related to the TRA.
(7) Assumes full exchange of noncontrolling interest units for Class A common
stock and the effect of securities that were anti-dilutive during the three and
nine months ended September 26, 2026.
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow
(unaudited)
($
mi…
Se… Nine Sept…
26, mont… 27, $ %
20… ended 2025 Chan… Cha…
──────────────────────────────────────────────────────────────────────────────
Net
ca…
pr… $ 2,1… $ 1,5… $ 637 42.0 %
by
op…
ac…
Net
ca… -348 -309 -39 12.6 %
ex…
Fr…
Ca… $ 1,8… $ 1,2… $ 598 49.6 %
Fl…